Microangiopathy in Cancer: Causes, Consequences, and Management

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Thrombotic microangiopathy (TMA) is a complex syndrome characterized by hemolytic anemia, low platelet counts, and microvascular thrombosis.
• Cancer and transplantation are significant risk factors for developing TMA, presenting unique clinical challenges.
• Chemotherapy agents and extensive cancer involvement in the bone marrow can precipitate TMA.

Purpose of the Study:

• To review the mechanisms and clinical manifestations of TMA in the context of cancer and transplantation.
• To highlight the diagnostic and therapeutic challenges associated with transplant-associated TMA (TA-TMA) and cancer-associated TMA.
• To discuss the limitations of current treatment modalities, including the ineffectiveness of plasma exchange for cancer-associated TMA.

Main Methods:

• Literature review of TMA in cancer and transplant patients.
• Analysis of mechanisms including microvascular metastases, bone marrow involvement, and drug toxicity.
• Examination of transplant-associated TMA (TA-TMA) in solid organ and hematopoietic stem cell transplant recipients.

Main Results:

• Cancer-associated TMA can arise from various mechanisms, including chemotherapy (gemcitabine, platinum drugs, mitomycin C, proteasome inhibitors).
• TA-TMA presents a high mortality rate and lacks standardized diagnostic criteria and effective therapies.
• Plasma exchange is not an effective treatment for TMA in cancer patients.

Conclusions:

• TMA is a critical complication in both cancer patients and transplant recipients, demanding further research.
• Developing standardized diagnostic criteria and effective therapeutic strategies for TA-TMA and cancer-associated TMA is crucial.
• Addressing the challenges of TMA in these populations requires novel treatment approaches beyond current standards of care.